Research from Weill Cornell Medicine indicates that state laws banning insurance prior authorization for buprenorphine, a key medication for opioid use disorder, may not effectively enhance patient retention in treatment. The findings, published on March 6, 2024, in the JAMA Health Forum, suggest that while these laws aim to improve access to treatment, they do not significantly increase the duration of time patients remain in care.
Buprenorphine is known to be a crucial therapy that alleviates cravings and withdrawal symptoms associated with opioid addiction. Despite its life-saving potential, adherence to this medication remains alarmingly low. The study focused on the retention rates of approximately 23,000 patients aged 18 to 64 who began buprenorphine treatment between January 2015 and June 2022. During this period, 19 states enacted laws prohibiting private insurance companies from imposing prior authorization requirements for buprenorphine.
The results revealed that less than one-third (30.4%) of patients remained in treatment for the recommended minimum of 180 days without experiencing gaps longer than seven days. Even when considering longer gaps, fewer than half of the participants (45.7%) maintained treatment without interruptions exceeding 30 days. Notably, patients in states with prior authorization bans did not show significant improvements in retention compared to those in states that still required these authorizations.
Yuhua Bao, the senior author and professor of population health sciences at Weill Cornell, emphasized the need for comprehensive strategies to tackle the challenges surrounding opioid treatment. “As more states enact prior authorization prohibitions to facilitate access to life-saving medications for opioid use disorder, our findings suggest that effective strategies will have to address multiple and interacting barriers such as requiring drug testing, counseling, or quantity limits for medication,” Bao stated.
The prior authorization process, which requires insurance approval before covering treatment, can delay the initiation of therapy, disrupt ongoing care, and hinder timely access to necessary medications. These delays are particularly detrimental given the current landscape of opioid addiction, where approximately 55,000 individuals succumbed to opioid overdoses in 2024, despite a notable decline in overdose deaths during the 2023-24 period.
Allison Ju-Chen Hu, the study’s first author and an assistant professor at Tulane University School of Public Health and Tropical Medicine, argued that legislative efforts alone may not be sufficient to close treatment gaps. “Without robust enforcement and monitoring of private insurers’ compliance – in addition to the implementation of complementary interventions – legislative bans on prior authorization may have limited impact on closing treatment gaps,” she remarked.
The study underscores the importance of broader policy actions to improve patient outcomes in opioid use disorder treatment. These include enhancing the availability of healthcare providers, reducing stigma associated with treatment, and facilitating access to counseling and recovery services. The research was supported by the National Institute on Drug Abuse, highlighting the ongoing need for effective strategies in addressing the opioid crisis.
This study serves as a critical reminder that while legislative measures are essential, they must be part of a multifaceted approach to ensure that individuals struggling with opioid use disorder can access and remain in effective treatment.
